Sable Bio closes €3.15 million seed round
UK-based Sable Bio, an emerging player in AI-driven drug safety, has raised €3.15 million to accelerate development of its predictive safety platform and expand its London operations. The funding underscores growing investor confidence in applying advanced machine learning and data science to reduce risk and cost across the pharmaceutical lifecycle.
AI platform targets safer, faster drug development
Sable Bio is building tools that use AI algorithms to anticipate potential drug safety issues earlier in research and clinical development. By integrating preclinical data, real‑world evidence and historical safety records, the startup aims to flag signals that traditional methods might miss, helping teams design safer molecules and better clinical trials.
The platform is designed for global pharma and biotech companies seeking to reduce late‑stage failures, regulatory setbacks and post‑marketing safety events. Earlier, data‑driven insight into toxicity and adverse events can translate into fewer trial delays, more efficient portfolios and improved outcomes for patients.
London team expansion and product roadmap
The new capital will primarily support hiring in London, where Sable Bio plans to grow its team of computational scientists, pharmacologists and software engineers. Strengthening local talent is expected to speed up product development, enhance the platform’s analytical depth and improve integration with existing drug discovery and pharmacovigilance workflows.
Alongside team growth, the startup is set to invest in product features that make complex safety analytics more accessible to non‑technical users. This includes dashboards for safety teams, APIs for integration with clinical systems and validation studies to meet stringent regulatory expectations.
Rising momentum for AI in life sciences
The round adds to a broader wave of investment into AI in healthcare, where tools that can de‑risk and streamline R&D are in high demand. As regulators and industry leaders push for more proactive safety monitoring, solutions like those from Sable Bio are positioned to become part of the standard toolkit for modern drug development.